Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Fighting Fire with Fire: Phage Potential for the Treatment of E. coli O157 Infection.

Howard-Varona C, Vik DR, Solonenko NE, Li YF, Gazitua MC, Chittick L, Samiec JK, Jensen AE, Anderson P, Howard-Varona A, Kinkhabwala AA, Abedon ST, Sullivan MB.

Antibiotics (Basel). 2018 Nov 16;7(4). pii: E101. doi: 10.3390/antibiotics7040101.

2.

Phage Therapy: Various Perspectives on How to Improve the Art.

Abedon ST.

Methods Mol Biol. 2018;1734:113-127. doi: 10.1007/978-1-4939-7604-1_11.

PMID:
29288451
3.

Basic Phage Mathematics.

Abedon ST, Katsaounis TI.

Methods Mol Biol. 2018;1681:3-30. doi: 10.1007/978-1-4939-7343-9_1. Review.

PMID:
29134583
4.

Bacteriophage Clinical Use as Antibacterial "Drugs": Utility and Precedent.

Abedon ST.

Microbiol Spectr. 2017 Aug;5(4). doi: 10.1128/microbiolspec.BAD-0003-2016. Review.

PMID:
28840811
5.

Editorial: Phage Therapy: Past, Present and Future.

Abedon ST, GarcĂ­a P, Mullany P, Aminov R.

Front Microbiol. 2017 Jun 15;8:981. doi: 10.3389/fmicb.2017.00981. eCollection 2017. No abstract available.

6.

Commentary: Communication between Viruses Guides Lysis-Lysogeny Decisions.

Abedon ST.

Front Microbiol. 2017 May 31;8:983. doi: 10.3389/fmicb.2017.00983. eCollection 2017. No abstract available.

7.

Information Phage Therapy Research Should Report.

Abedon ST.

Pharmaceuticals (Basel). 2017 Apr 30;10(2). pii: E43. doi: 10.3390/ph10020043.

8.

Lysogeny in nature: mechanisms, impact and ecology of temperate phages.

Howard-Varona C, Hargreaves KR, Abedon ST, Sullivan MB.

ISME J. 2017 Jul;11(7):1511-1520. doi: 10.1038/ismej.2017.16. Epub 2017 Mar 14.

9.

Phage therapy dosing: The problem(s) with multiplicity of infection (MOI).

Abedon ST.

Bacteriophage. 2016 Aug 11;6(3):e1220348. eCollection 2016 Jul-Sep.

10.

Commentary: Phage Therapy of Staphylococcal Chronic Osteomyelitis in Experimental Animal Model.

Abedon ST.

Front Microbiol. 2016 Aug 10;7:1251. doi: 10.3389/fmicb.2016.01251. eCollection 2016. No abstract available.

11.

Diversity of phage infection types and associated terminology: the problem with 'Lytic or lysogenic'.

Hobbs Z, Abedon ST.

FEMS Microbiol Lett. 2016 Apr;363(7). pii: fnw047. doi: 10.1093/femsle/fnw047. Epub 2016 Feb 29. Review.

PMID:
26925588
12.

Bacteriophage exploitation of bacterial biofilms: phage preference for less mature targets?

Abedon ST.

FEMS Microbiol Lett. 2016 Feb;363(3). pii: fnv246. doi: 10.1093/femsle/fnv246. Epub 2016 Jan 6.

PMID:
26738755
13.

Phage therapy of pulmonary infections.

Abedon ST.

Bacteriophage. 2015 Apr 18;5(1):e1020260. eCollection 2015 Jan-Mar. Review.

14.

Ecology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm Bacteria.

Abedon ST.

Pharmaceuticals (Basel). 2015 Sep 9;8(3):559-89. doi: 10.3390/ph8030559. Review.

15.

Ecology of Anti-Biofilm Agents I: Antibiotics versus Bacteriophages.

Abedon ST.

Pharmaceuticals (Basel). 2015 Sep 9;8(3):525-58. doi: 10.3390/ph8030525. Review.

16.

Re-establishing a place for phage therapy in western medicine.

Kutter EM, Kuhl SJ, Abedon ST.

Future Microbiol. 2015;10(5):685-8. doi: 10.2217/fmb.15.28. Review. No abstract available.

17.

Bacteriophage secondary infection.

Abedon ST.

Virol Sin. 2015 Feb;30(1):3-10. doi: 10.1007/s12250-014-3547-2. Epub 2015 Jan 13. Review.

PMID:
25595214
18.

Virus ecology and disturbances: impact of environmental disruption on the viruses of microorganisms.

Allen HK, Abedon ST.

Front Microbiol. 2014 Dec 12;5:700. doi: 10.3389/fmicb.2014.00700. eCollection 2014. No abstract available.

19.

Bacteriophages and their enzymes in biofilm control.

Chan BK, Abedon ST.

Curr Pharm Des. 2015;21(1):85-99. Review.

PMID:
25189866
20.

Phage therapy: eco-physiological pharmacology.

Abedon ST.

Scientifica (Cairo). 2014;2014:581639. doi: 10.1155/2014/581639. Epub 2014 May 20. Review.

Supplemental Content

Loading ...
Support Center